|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2009-1-26
|
|
pubmed:abstractText |
Liquid chromatography coupled to mass spectrometry (LC/MS) was used to elucidate early biomarkers of bortezomib response in multiple myeloma patients. The change in serum myeloma M-protein level, maintained for a minimum of 6 weeks, is used as one of the main criteria to evaluate patient clinical response to therapy. The objective of this study was to identify biomarkers using LC/MS in order to predict patient response to bortezomib sooner and more accurately compared to serum M-protein levels. The plasma LC/MS biomolecular/biochemical profiles, comprised of thousands of endogenous small molecules, peptides and proteins, were determined for 10 multiple myeloma patients at predose and 24 h after initial dosing with bortezomib. The comparative analysis of the metabolic profiles of non-responders and partial responders provided an opportunity to investigate mechanisms related to disease progression and identify biomarkers related to drug response. The plasma levels of two potential efficacy response markers were significantly more abundant in the non-responsive patients compared to the responders at 24-h postdose. The potential response biomarkers, apolipoprotein C-I and apolipoprotein C-I', were identified by mass spectral analyses and confirmed by authentic protein standards based on MALDI-TOF MS/MS sequencing of proteolytic peptides.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0731-7085
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
49
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
115-22
|
|
pubmed:meshHeading |
pubmed-meshheading:19062221-Aged,
pubmed-meshheading:19062221-Antineoplastic Agents,
pubmed-meshheading:19062221-Apolipoprotein C-I,
pubmed-meshheading:19062221-Biological Markers,
pubmed-meshheading:19062221-Blood Proteins,
pubmed-meshheading:19062221-Boronic Acids,
pubmed-meshheading:19062221-Chromatography, Liquid,
pubmed-meshheading:19062221-Clinical Trials, Phase II as Topic,
pubmed-meshheading:19062221-Disease Progression,
pubmed-meshheading:19062221-Female,
pubmed-meshheading:19062221-Humans,
pubmed-meshheading:19062221-Male,
pubmed-meshheading:19062221-Mass Spectrometry,
pubmed-meshheading:19062221-Middle Aged,
pubmed-meshheading:19062221-Molecular Weight,
pubmed-meshheading:19062221-Multiple Myeloma,
pubmed-meshheading:19062221-Protein Isoforms,
pubmed-meshheading:19062221-Pyrazines,
pubmed-meshheading:19062221-Reference Standards,
pubmed-meshheading:19062221-Reproducibility of Results,
pubmed-meshheading:19062221-Spectrometry, Mass, Matrix-Assisted Laser...,
pubmed-meshheading:19062221-Tandem Mass Spectrometry,
pubmed-meshheading:19062221-Time Factors
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Elucidation of potential bortezomib response markers in mutliple myeloma patients.
|
|
pubmed:affiliation |
Nextcea, Inc., 600 West Cummings Park, #6375, Woburn, MA 01801, United States. frank.hsieh@nextcea.com
|
|
pubmed:publicationType |
Journal Article
|
